From: Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
Adverse Event | All Events | CTCAE Grade | ||
---|---|---|---|---|
1 | 2 |  ≥ 3 | ||
RCCEP | 14 (70.0%) | 10 (50.0%) | 4 (20.0%) | 0 (0%) |
Asthenia | 4 (20.0%) | 4(20.0%) | 0 (0%) | 0 (0%) |
Rash | 4 (20.0%) | 4 (20.0%) | 0(0%) | 0 (0%) |
Hypothyroidism | 2 (10.0%) | 2 (10.0%) | 0 (0%) | 0 (0%) |
Pneumonitis | 1 (5.0%) | 1 (5.0%) | 0 (0%) | 0 (0%) |